ddrg/super_eurlex huggingface dataset:
Official Journal of the European Union

Prior notification of a concentration

(Case M.10559 – A P MOELLER-MAERSK / SENATOR INTERNATIONAL)

(Text with EEA relevance)

(2022/C 100/09)

1. On 22 February 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — A.P. Møller-Mærsk A/S Group (‘APMM’, Denmark), — Senator International group (‘Senator International’, Germany). APMM will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Senator International. The concentration is accomplished by way of purchase of shares and assets.

2. The business activities of the undertakings concerned are: — APMM: integrated transport and logistics company with worldwide activities. APMM’s core activities comprise container liner shipping through its subsidiaries Maersk A/S, SeaLand, and Hamburg Süd, container terminal services, inland transportation, inland services, supply chain management services, harbour towage and reefer container manufacturing, — Senator International: family-owned company primarily specialized in international freight, shipping and logistics, with its main focus on air and ocean freight forwarding, as well as logistics, packaging and customs services.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10559 – A P MOELLER-MAERSK / SENATOR INTERNATIONAL Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
Non-opposition to a notified concentration

(Case M.10625 – CARLYLE GROUP / MACQUARIE GROUP / HYCC)

(Text with EEA relevance)

(2022/C 120/03)

On 9 March 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10625. EUR-Lex is the online point of access to European Union law.

(1) OJ L 24, 29.1.2004, p. 1.
Withdrawal of notification of a concentration

(Case M.10319 – GREINER / RECTICEL)

(Text with EEA relevance)

(2022/C 114/01)

On 18 October 2021, the European Commission received notification (1) of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (2) (‘Merger Regulation’).

On 24 November 2021, the Commission decided to initiate proceedings (3) under Article 6(1)(c) of the Merger Regulation. On 28 February 2022, the notifying party informed the Commission that it withdrew its notification and demonstrated that it abandoned the concentration.

(1) OJ C 432, 26. 10. 2021, p. 7.

(2) OJ L 24, 29.1.2004, p. 1.

(3) OJ C 483, 1. 12. 2021, p. 2.
Opinion of the Advisory Committee on mergers at its meeting of 30 April 2021 concerning a preliminary draft decision relating to Case M.8181 – Merck / Sigma-Aldrich – Art. 14(1) procedure

Rapporteur: Romania

(2022/C 134/03)

1. The Advisory Committee (13 Member States) agrees with the Commission’s assessment that Sigma-Aldrich submitted incorrect and/or misleading information, within the meaning of Article 14(1)(a) of Council Regulation (EC) No 139/2004 (the ‘Merger Regulation’), in Section 5.3 of the Final Form RM submitted on 12 June 2015 pursuant to Article 20(1a) of Commission Regulation (EC) No 802/2004 (the ‘Implementing Regulation’).

2. The Advisory Committee (13 Member States) agrees with the Commission’s assessment that Sigma-Aldrich submitted incorrect and/or misleading information, within the meaning of Article 14(1)(b) of the Merger Regulation, in reply to the 29 May 2015 request for information made pursuant to Article 11(2) of the Merger Regulation.

3. The Advisory Committee (13 Member States) agrees with the Commission’s assessment that Sigma-Aldrich submitted incorrect and/or misleading information, within the meaning of Article 14(1)(b) of the Merger Regulation, in reply to the 2 June 2015 request for information made pursuant to Article 11(2) of the Merger Regulation.

4. The Advisory Committee (13 Member States) agrees with the Commission’s assessment that Sigma-Aldrich intentionally or at least negligently infringed Article 14(1)(a) of the Merger Regulation by submitting incorrect and/or misleading information in Section 5.3 of the Final Form RM submitted on 12 June 2015 pursuant to Article 20(1a) of the Implementing Regulation.

5. The Advisory Committee (13 Member States) agrees with the Commission’s assessment that Sigma-Aldrich intentionally or at least negligently infringed Article 14(1)(b) of the Merger Regulation by submitting incorrect and/or misleading information in reply to the 29 May 2015 request for information made pursuant to Article 11(2) of the Merger Regulation.

6. The Advisory Committee (13 Member States) agrees with the Commission’s assessment that Sigma-Aldrich intentionally or at least negligently infringed Article 14(1)(b) of the Merger Regulation by submitting incorrect and/or misleading information in reply to the 2 June 2015 request for information made pursuant to Article 11(2) of the Merger Regulation.

7. The Advisory Committee (13 Member States) agrees with the Commission that a fine should be imposed on Sigma-Aldrich pursuant to Articles 14(1)(a) and 14(1)(b) of the Merger Regulation.

8. The Advisory Committee (13 Member States) agrees with the factors taken into consideration by the Commission for the purposes of determining the level of the fine to be imposed on Sigma-Aldrich pursuant to Articles 14(1)(a) and 14(1)(b) of the Merger Regulation.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10602 – SWISS LIFE INTERNATIONAL HOLDING / ELIPS LIFE)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 123/07)

1. On 10 March 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Swiss Life International Holding AG (‘Swiss Life’, Switzerland), — Elips Life AG (‘ELAG’, Liechtenstein) and the A&H insurance portfolio of Elips Versicherungen AG (‘A&H’, Liechtenstein, together with ELAG referred to as ‘ELAG-A&H’), both controlled by elipsLife EMEA Holding B.V. (Netherlands), itself ultimately controlled by Swiss Re Ltd (Switzerland). Swiss Life will acquire, within the meaning of Article 3(1)(b) of the Merger Regulation, sole control of the whole of ELAG-A&H. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following: — Swiss Life is a European provider of life insurance, risk, pensions, asset management and other financial products, — ELAG-A&H is a European insurance company providing a range of insurance products to institutional clients (B2B business).

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10602 – SWISS LIFE INTERNATIONAL HOLDING / ELIPS LIFE Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10611 – GENERALI FRANCE / LA MÉDICALE)

(Text with EEA relevance)

(2022/C 147/01)

On 23 March 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10611. EUR-Lex is the online point of access to European Union law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10636 – COVÉA / PARTNERRE)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 139/05)

1. On 21 March 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Covéa Coopérations (‘Covéa’, France) controlled by Covéa SGAM (France), — PartnerRe Ltd (‘PartnerRe’, Bermuda), controlled by Exor N.V. (Netherlands). Covéa will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of PartnerRe. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned: — Covéa is a mutual group headquartered in France active in life and non-life insurance, and to a minor extent in reinsurance, insurance distribution and asset management, — PartnerRe is a global reinsurance company headquartered in Bermuda.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10636 – COVÉA / PARTNERRE Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Prior notification of a concentration

(Case M.10707 – MACQUARIE / BCI / REDEN HOLDING AND REDEN HOLDING 2020)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 160/12)

1. On 4 April 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Macquarie Group Limited (Macquarie, UK), — British Columbia Investment Management Corporation (BCI, Canada), — Reden Holding and Reden Holding 2020 (Target, France). Macquarie and BCI will acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of the Target. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following: — Macquarie is a global investment bank and financial services provider covering resources and commodities, green energy, conventional energy, financial institutions, infrastructure and real estate, — BCI is an agent of the Government of British Columbia in Canada, which invests on behalf of public sector clients in British Columbia and helps finance the retirement benefits of approx. 690 000 plan members, as well as insurance and benefit funds that cover 2,5 million workers in British Columbia, — The Target develops, finances, builds and operates solar photovoltaic power plants in Europe, in particular, in France, Greece, Italy, Portugal and Spain, and in Latin America.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10707 — MACQUARIE / BCI / REDEN HOLDING AND REDEN HOLDING 2020 Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10647 – HOYA / BOE Vision / JV)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 157/07)

1. On 4 April 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — HOYA Corporation (‘HOYA’, Japan), — Beijing BOE Vision Electronic Technology Co., Ltd. (‘BOE Vision’, People’s Republic of China, controlled by BOE Technology Group Co., Ltd. (People’s Republic of China), — HOYA BOE Microelectronics China Ltd., a newly created company constituting a joint venture (‘JV’, People’s Republic of China), jointly controlled by HOYA and BOE Vision. HOYA and BOE Vision will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of JV. The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.

2. The business activities of the undertakings concerned and the newly set-up joint venture are the following: — HOYA: research and development, manufacturing and sale of electronic products, including photomask blanks, photomasks and glass substrates for hard drive disks, — BOE Vision: liquid crystal display manufacturing and technology development, technology transfer, technical consultation and technical services for liquid crystal display television, television and other end products and systems, — JV: production and sale of photomasks for use in the production of flat panel displays.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10647 – HOYA / BOE Vision / JV Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Prior notification of a concentration

(Case M.10684 – SWISS LIFE / VAUBAN / WASCOSA)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 172/03)

1. On 19 April 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Swiss Life Holding AG (‘Swiss Life’, Switzerland), — Vauban Infrastructure Partners SCA (‘Vauban’, France), controlled by BPCE S.A. (France), — Wascosa Holding AG (‘Wascosa’, Switzerland). Swiss Life and Vauban will acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Wascosa. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned: — Swiss Life is a European provider of comprehensive life pensions and financial solutions. It is active in the EU, Switzerland, the UK, Liechtenstein and Singapore. Swiss Life is active in the life insurance sector and the investment and asset management segment; it also provides multinational corporations with employee benefit solutions, — Vauban is a European asset management company with a focus on infrastructure equity investments with a strong focus in France but also direct investments in Finland, Italy, Norway, Portugal and Spain. It structures and manages equity funds investing in the design, construction, maintenance, financing and operation of essential infrastructure assets in the transportation, social, digital and utilities sectors, — Wascosa is an internationally active freight wagons rental and management company. Its activities include the pan-European leasing of freight wagons, the management of customers’ own wagon fleets and advice on maintenance, insurance and safety around freight wagons.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10684 – SWISS LIFE / VAUBAN / WASCOSA Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Prior notification of a concentration

(Case M.10674 – INTERPARKING SERVIZI / OSR / PARKING LOT JV)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 168/15)

1. On 11 April 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Interparking Servizi S.r.l. (‘Interparking’, Italy), belonging to the Ageas Group, — Ospedale San Raffaele S.r.l. (‘OSR’, Italy), belonging to Gruppo San Donato (‘GSD’), — Three parking lots located in the San Raffaele area in Milan, one belonging to OSR and the other two to Universita Vita-Salute San Raffaele and MM S.pA (the ‘Target’, Milan). Interparking and OSR will acquire within the meaning of Articles 3(1)(b) and 3(4) of the Merger Regulation joint control of the Target through a newly created JV (the ‘JV’). The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture and by way of purchase of assets.

2. The business activities of the undertakings concerned: — Interparking is active in the management of paid parking lots in Italy. Interparking is controlled by Ageas Group, which mainly provides life and non-life insurance services to personal, business and institutional customers, active in Europe and in Asia, — OSR is a Scientific Hospitalization and Care Institute, part of Gruppo San Donato, a private hospital group in Italy, — The Target consists of (i) an off-street parking lot and related assets located in Milan, in the area nearby the San Raffaele Hospital, currently owned by OSR and managed by a third party, as well as (ii) two parking lots (‘P6 and P7’) located in the same area, owned by Universita Vita-Salute San Raffaele and MM S.pA, and managed by OSR.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10674 – INTERPARKING SERVIZI / OSR / PARKING LOT JV Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.